More treatment but no less depression: five researchers test seven explanations for the paradox
"Treatments for depression have improved, and their availability has markedly increased since the 1980s. Mysteriously the general population prevalence of depression has not decreased."
Weak or heavily disputed. Treat as a question, not an answer. how we score evidence
Caveat on this rating: A narrative evaluation of explanations, not a systematic review with a pooled estimate. Prevalence surveys have their own measurement problems, and the authors weigh rather than rule out the possibility that rising willingness to report symptoms masks an improvement.
If a treatment works and far more people get it, the condition should become less common. For depression it has not. This paper gave the problem a name and tried to solve it.
Significant findings
Ormel, Hollon, Kessler, Cuijpers and Monroe (Clinical Psychology Review, 2022) call it the "treatment-prevalence paradox" and "propose and evaluate seven explanations". Two assume treatment did lower prevalence but something hid it: more distress being misdiagnosed as depression, or a real rise in new cases. Five assume prevalence truly did not fall: treatments are "less efficacious" and "less enduring than the literature suggests"; "trial efficacy doesn't generalize to real-world settings"; impact "differs for chronic-recurrent versus non-recurrent cases"; and "treatments have some iatrogenic consequences".
Their verdict: "there is little evidence that incidence or prevalence have increased as a result of error or fact", and "strong evidence that (a) the published literature overestimates short- and long-term treatment efficacy, (b) treatments are considerably less effective as deployed in "real world" settings, and (c) treatment impact differs substantially for chronic-recurrent cases relative to non-recurrent cases. Collectively, these a-c explanations likely account for most of the TPP."
On harm from treatment itself: "little research exists on iatrogenic effects of current treatments (Explanation 7), but further exploration is critical."
Worth asking
These are not outsiders. Kessler ran the US national comorbidity surveys; Hollon and Cuijpers are among the most cited depression treatment researchers alive. Their answer is not that treatment does nothing. It is that treatment does less than the journals say, less again outside a trial, and least for the recurrent cases that make up most of the prevalence. That is an argument for better care and honest numbers, not for going without.
Source
More treatment but no less depression: The treatment-prevalence paradox — Ormel J, Hollon SD, Kessler RC, Cuijpers P, Monroe SM (2022)
Reputable peer-reviewed journal
Read the source: https://doi.org/10.1016/j.cpr.2021.102111
DOI: 10.1016/j.cpr.2021.102111
How this was scored
- Study design
- Narrative review
- Funding
- Funding not disclosed
- Published in
- Reputable peer-reviewed journal
- Sample size
- not recorded
- Preregistered
- not recorded
- Conflicts disclosed
- not recorded
- Independent of proponent
- not recorded
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published September 21, 2026.
Questions
How strong is the evidence behind this?
veisund rates this source "contested". Weak or heavily disputed. Treat as a question, not an answer. It scores 33 out of 100 on our published rubric. One caveat travels with that badge: A narrative evaluation of explanations, not a systematic review with a pooled estimate. Prevalence surveys have their own measurement problems, and the authors weigh rather than rule out the possibility that rising willingness to report symptoms masks an improvement. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
More treatment but no less depression: The treatment-prevalence paradox — Ormel J, Hollon SD, Kessler RC, Cuijpers P, Monroe SM (2022). Published in: Reputable peer-reviewed journal. DOI: 10.1016/j.cpr.2021.102111. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Narrative review. Funding: Funding not disclosed. Independence from the proponent is not recorded. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.